Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial
To compare effects of full spectrum hemp-derived CBD (FS-CBD, 200mg), to CBD alone (200mg CBD), and placebo on the primary outcome measures (CDR-SB score, plasma N-p-tau181, plasma Aβ42/Aβ40 ratio, Nfl) and secondary outcome measures (pain, sleep quantity/quality, anxiety) over the course of a 24-week RCT
1. Must be between the ages of 55 - 85 and provide valid informed consent. 2. Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician.
University of Colorado Hospital
Kent Hutchison, PhD
Protocol Number: 23-0619
More information available at ClinicalTrials.gov: NCT05822362
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers